Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Reed Miller
Device Debuts is a new regular feature highlighting Medtech Insight editors’ top picks of medical devices that have been commercialized for the first time in the last month. This edition features an innovative minimally invasive surgical stapler, a pain-free blood-collection device, a novel approach for collecting, circulating tumor cells, a rapid fluid-infusion device for critically ill patients, and an EP-mapping and navigation system.
The worldwide voluntary removal comes in response to reports that the pin that connects the valve to the delivery system sometimes releases prematurely, most likely due to excess tension created during manufacturing.
The medtech giant announced 6% revenue growth, led by the cardiac and vascular and diabetes groups, both of which are enjoying strong market demand for new products. Medtronic expects to continue growing revenues by about five percent annually to maintain double-digit earnings growth.
The final five-year results from the STAMPEDE trial, said to be the first randomized controlled trial in the bariatric space, show that bariatric surgery plus intensive medical therapy is more effective than intensive medical therapy alone in combating hyperglycemia in obese patients with type 2 diabetes.
UK's National Institute for Health and Care Excellence has recommended the HeartFlow FFRct Analysis for stable patients with a suspected myocardial infarction. NICE was won over by the potential £9m savings that the technology can bring to the National Health Services in the next five years.
Hologic is acquiring Cynosure for $1.65bn, saying medical aesthetics will complement its existing OB/GYN and women’s health businesses. It is the latest in a series of recent moves intended to accelerate Hologic’s growth.